Skip to main
TECH
TECH logo

Bio-Techne (TECH) Stock Forecast & Price Target

Bio-Techne (TECH) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 45%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Bio-Techne is projected to report revenues of $315.0 million, reflecting a 3% increase compared to the previous quarter, indicating consistent growth in its operations. The adjusted earnings per share are anticipated to reach $0.50, which represents a year-over-year improvement from $0.49, suggesting solid financial performance in the face of market conditions. The company's strong foothold in the life sciences sector, particularly within its protein sciences segment, underpins a positive outlook for sustained revenue and earnings growth moving forward.

Bears say

Bio-Techne faces a challenging outlook due to the anticipated escalation of U.S. tariffs and proposed cuts in funding for U.S. agencies, including the NIH, which are likely to adversely affect revenue and gross margins for the fourth quarter of 2025. The firm is adjusting its estimates for that quarter, indicating expectations of slower-than-anticipated revenue and margin performance. The concentrated impact of these external economic factors on approximately 75% of its revenue from the protein sciences segment raises fundamental concerns regarding ongoing financial stability.

Bio-Techne (TECH) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 45% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bio-Techne (TECH) Forecast

Analysts have given Bio-Techne (TECH) a Buy based on their latest research and market trends.

According to 11 analysts, Bio-Techne (TECH) has a Buy consensus rating as of Oct 22, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $71.09, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $71.09, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bio-Techne (TECH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.